4.1 Review

Neurodegeneration in multiple sclerosis: novel treatment strategies

期刊

EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 12, 期 9, 页码 1061-1076

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.12.59

关键词

multiple sclerosis; neurodegeneration; neuronal injury; neuroprotection; treatment

资金

  1. Teva
  2. Novartis
  3. Merck Serona
  4. Bayer
  5. Johnson Johnson
  6. Ono
  7. Octapharma

向作者/读者索取更多资源

In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据